

Biosimilar statement from IBD Working Group

July 2015

Dear Members,

Re: Biosimilars use in paediatric IBD in the UK

We have been contacted by several members and others asking whether the BSPGHAN IBD WG group will be releasing a position statement on the use of biosimilars. We have discussed this in the working group and have agreed that this is not necessary as there is already a statement to this effect produced by the BSG. The BSPGHAN IBD WG has simply chosen to endorse the statement produced by the BSG on this topic.

We would especially emphasise that all patients receiving biologics (Remicade, Remsima, Inflectra as well as Humira) should be wherever possible have their details inputted into the biologics register <https://www.ibdbiologicsaudit.org> . Please note patients in the PANTS study will automatically have their data transferred into the biologics audit.

Your participation in the biologics audit has been excellent and this will allow us to look nationally with confidence (if participation rates remain high) at the impact biosimilars will have to our practice. The latest report from the “data lock” in February 2015 has produced interesting results and will be released in a national report in September 2015. The next “data lock” will then be in February 2016 which may then allow incorporation of data from patients on biosimilars dependant on usage.

Relevant articles:

UK opinion piece including BSG position statement:

http://fg.bmj.com/content/early/2015/07/20/flgastro-2015-100587.short?g=w_fg Ahead Tab

ESPGHAN position statement:

http://journals.lww.com/jpgn/Fulltext/publishahead/Use_of_Biosimilars_in_Paediatric_Inflammatory.97858.aspx

Best Wishes and happy summer

Richard Russell IBG WG chair on behalf of the BSPGHAN IBD WG